Advertisement
Case report| Volume 37, 101420, January 2020

Transient MOG antibody seroconversion associated with immunomodulating therapy

  • Marc Pawlitzki
    Correspondence
    Corresponding author.
    Affiliations
    Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany

    Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany
    Search for articles by this author
  • Christin Campe
    Affiliations
    Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany
    Search for articles by this author
  • Leoni Rolfes
    Affiliations
    Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany
    Search for articles by this author
  • Hans-Jochen Heinze
    Affiliations
    Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany

    Leibniz Institute, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany
    Search for articles by this author
  • Frank Leypoldt
    Affiliations
    Neuroimmunology, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Germany
    Search for articles by this author
  • Klaus-Peter Wandinger
    Affiliations
    Neuroimmunology, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Lübeck, Germany
    Search for articles by this author
  • Markus Reindl
    Affiliations
    Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
    Search for articles by this author
  • Brigitte Wildemann
    Affiliations
    Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Sven Jarius
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Peter Körtvelyessy
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany

    Charité-Universitätsmedizin Berlin, Department of Neurology, Germany

    German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany

    German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
Published:September 28, 2019DOI:https://doi.org/10.1016/j.msard.2019.101420

      Highlights

      • MOG-IgG was seronegative during both inflammatory events.
      • Seroconversion was transient and during interferon-beta treatment.
      • No disease progression was observed under interferon-beta therapy.

      Abstract

      Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Di Pauli F.
        • Mader S.
        • Rostasy K.
        • Schanda K.
        • Bajer-Kornek B.
        • Ehling R.
        • Deisenhammer F.
        • Reindl M.
        • Berger T.
        Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.
        Clinical immunology (Orlando, Fla.). 2011; 138: 247-254https://doi.org/10.1016/j.clim.2010.11.013
        • Höftberger R.
        • Sepulveda M.
        • Armangue T.
        • Blanco Y.
        • Rostásy K.
        • Calvo A.C.
        • Olascoaga J.
        • Ramió-Torrentà L.
        • Reindl M.
        • Benito-León J.
        • Casanova B.
        • Arrambide G.
        • Sabater L.
        • Graus F.
        • Dalmau J.
        • Saiz A.
        Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
        Mult. Scler. 2015; 21: 866-874https://doi.org/10.1177/1352458514555785
        • Jarius S.
        • Paul F.
        • Aktas O.
        • Asgari N.
        • Dale R.C.
        • Seze J.de
        • Franciotta D.
        • Fujihara K.
        • Jacob A.
        • Kim H.J.
        • Kleiter I.
        • Kümpfel T.
        • Levy M.
        • Palace J.
        • Ruprecht K.
        • Saiz A.
        • Trebst C.
        • Weinshenker B.G.
        • Wildemann B.
        MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
        J. Neuroinflammation. 2018; 15: 134https://doi.org/10.1186/s12974-018-1144-2
        • Jarius S.
        • Ruprecht K.
        • Kleiter I.
        • Borisow N.
        • Asgari N.
        • Pitarokoili K.
        • Pache F.
        • Stich O.
        • Beume L.-.A.
        • Hümmert M.W.
        • Ringelstein M.
        • Trebst C.
        • Winkelmann A.
        • Schwarz A.
        • Buttmann M.
        • Zimmermann H.
        • Kuchling J.
        • Franciotta D.
        • Capobianco M.
        • Siebert E.
        • Lukas C.
        • Korporal-Kuhnke M.
        • Haas J.
        • Fechner K.
        • Brandt A.U.
        • Schanda K.
        • Aktas O.
        • Paul F.
        • Reindl M.
        • Wildemann B.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
        J. Neuroinflammation. 2016; 13: 280https://doi.org/10.1186/s12974-016-0718-0
        • Krumbholz M.
        • Faber H.
        • Steinmeyer F.
        • Hoffmann L.-A.
        • Kümpfel T.
        • Pellkofer H.
        • Derfuss T.
        • Ionescu C.
        • Starck M.
        • Hafner C.
        • Hohlfeld R.
        • Meinl E.
        Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
        Brain : J. Neurol. 2008; 131: 1455-1463https://doi.org/10.1093/brain/awn077
        • Palace J.
        • Leite M.I.
        • Nairne A.
        • Vincent A.
        Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
        Arch. Neurol. 2010; 67: 1016-1017https://doi.org/10.1001/archneurol.2010.188
        • Spadaro M.
        • Gerdes L.A.
        • Krumbholz M.
        • Ertl-Wagner B.
        • Thaler F.S.
        • Schuh E.
        • Metz I.
        • Blaschek A.
        • Dick A.
        • Brück W.
        • Hohlfeld R.
        • Meinl E.
        • Kümpfel T.
        Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.
        Neurology(R) Neuroimmunology & Neuroinflammation. 2016; 3: e257https://doi.org/10.1212/NXI.0000000000000257
        • Wandinger K.-.P.
        • Stürzebecher C.-.S.
        • Bielekova B.
        • Detore G.
        • Rosenwald A.
        • Staudt L.M.
        • McFarland H.F.
        • Martin R.
        Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes.
        Ann Neurol. 2001; 50: 349-357https://doi.org/10.1002/ana.1096